Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 9—September 2022
Research

Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019

Yousra KherabiComments to Author , Mathilde Fréchet-Jachym, Christophe Rioux, Yazdan Yazdanpanah, Frédéric Méchaï, Valérie Pourcher, Jérôme Robert, Lorenzo Guglielmetti, and for the MDR-TB Management Group
Author affiliations: Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France (Y. Kherabi, C. Rioux, Y. Yazdanpanah); Sorbonne Université, INSERM U1135, Paris (Y. Kherabi, J. Robert, L. Guglielmetti); Centre Hospitalier de Bligny, Briis-sous-Forges, France (M. Frechet-Jachym); Assistance Publique—Hopitaux de Paris, Paris (C. Rioux, Y. Yazdanpanah); INSERM U1137, IAME, Université de Paris, Paris (Y. Yazdanpanah); Universite Paris Diderot, Paris (Y. Yazdanpanah); Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, Paris (F. Méchaï); Hopital Avicenne, Bobigny, France (F. Méchaï); Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris (V. Pourcher); Assistance Publique Hôpitaux de Paris, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris (J. Robert, L. Guglielmetti)

Main Article

Table 4

Risk factors for unsuccessful outcomes in patients affected by MDR TB, France, 2006–2019*

Characteristic aOR (95% CI) p value
TB resistance status
Fluoroquinolone-susceptible MDR Referent
Pre-XDR/XDR
 0.81 (0.47–1.41)
 0.48
History of anti-TB treatment
No Referent
Yes
 2.16 (1.32–3.55)
 0.002
Treatment adherence†
Good Referent
Poor
 1.21 (1.08–1.35)
 0.001
HCV coinfection
No Referent
Yes
 0.63 (0.36–1.10)
 0.11
Immunosuppression‡
No Referent
Yes
 1.56 (0.50–4.89)
 0.44
Pulmonary tuberculosis
No Referent
Yes 2.92 (0.90–9.50) 0.07

*We used multivariable logistic regression with multiple imputation for missing data. Results are from the final model. aOR, adjusted odds ratio; MDR, multidrug resistant (susceptible to all fluoroquinolones); NS, not statistically significant; pre-XDR/XDR, pre–extensively drug resistant/extensively drug resistant, (resistant to >1 fluoroquinolone); TB, tuberculosis. †Assessed by treating physician. ‡Immunosuppressive disease and/or immunosuppressive treatment.

Main Article

Page created: July 31, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external